Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults with Chronic Inducible Urticaria

Next Previous
X
Search
Trial Profile

An Open Label Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults with Chronic Inducible Urticaria

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EVO 756 (Primary)
  • Indications Chronic urticaria; Cold Urticaria; Familial dermographism
  • Focus Adverse reactions
  • Sponsors Evommune

    • Most Recent Events

    • 11 Sep 2024 New trial record
    • 03 Sep 2024 According to an Evommune media release, company announced the enrollment of the first patient in a Phase 2 trial of EVO756 in adults with CIndU.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top